现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • Vecabrutinib (SNS-062)
Vecabrutinib (SNS-062)的可视化放大

Vecabrutinib (SNS-062)

Vecabrutinib (SNS-062) (SNS-062) 是一种有效的非共价 BTK 和 ITK 抑制剂,Kd 值分别为 0.3 nM 和 2.2 nM。 Vecabrutinib (SNS-062) 对 ITK 的 IC50 为 24 nM。

原价
¥4312-33225
价格
3450-26580
Vecabrutinib (SNS-062)的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajce52396
  • CAS: 1510829-06-7
  • 别名: 维卡布鲁替尼,SNS-062
  • 分子式: C22H24ClF4N7O2
  • 分子量: 529.92
  • 纯度: >98%
  • 溶解度: DMSO : 125 mg/mL (235.88 mM)
  • 储存: Store at -20°C
  • 库存: 现货

Background

Vecabrutinib is a potent, noncovalent BTK and ITK inhibitor, with Kd of 0.3 nM and 2.2 nM, respectively; Vecabrutinib shows an IC50 of 24 nM for ITK.


Vecabrutinib inhibits pBTK in human whole blood with an average IC50 of 50 nM. Vecabrutinib inhibits WT and C481S BTK with similar IC50s (pBTK IC50s: WT BTK 2.9 nM, C481S BTK 4.4 nM)[1]. In a recombinant kinase assay, IC50s of Vecabrutinib against WT BTK and C481S BTK are 4.6 nM and 1.1 nM. Vecabrutinib retains activity against the mutated BTK variant. Vecabrutinib is six times more potent than ibrutinib and greater than 640 times more potent than acalabrutinib against C481S BTK. Vecabrutinib demonstrates dose-dependent inhibition of BTK in primary patient CLL cells comparable to ibrutinib via immunoblot for BTK phosphorylation. Vecabrutinib decreases viability of primary CLL cells in the presence of HS5 stromal protection by 5.5%[2].


Vecabrutinib has good oral bioavailability in rat and dog (%F ≥ 40%) and a terminal half-life of 5 to 6 hours. Vecabrutinib is well tolerated with continuous drug levels and at exposures much greater than those achieved for ibrutinib[1].


[1]. Minke E. Binnerts, et al. Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation. Molecular Cancer Therapeutics. December 2015 Volume 14, Issue 12 Supplement 2 [2]. Catherine A. Fabian, et al. Abstract 1207: SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase. Cancer Research July 2017 Volume 77, Issue 13 Supplement

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服